Virtus LifeSci Biotech Clinical Trials ETF
21 hedge funds and large institutions have $15.2M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Holders
21
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$1.41M | |
| 2 | +$244K | |
| 3 | +$200K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$54K |
| 5 |
ODG
O'Dell Group
Cincinnati,
Ohio
|
+$5K |
Top Sellers
| 1 | -$373K | |
| 2 | -$318K | |
| 3 | -$243K | |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$204K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$10.2K |